DUBLIN--(BUSINESS WIRE)--The "Infectious Disease Diagnostics Market by Product (Reagents, Kits, Instrument, Software), Test Type (Lab, POC), Disease (COVID-19, Flu, HAIs, HIV, HPV), Technology (Immunodiagnostics, NGS, INAAT, PCR), End User (Hospitals, Labs) - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
The global infectious disease diagnostics market size is projected to reach USD 33.1 billion by 2027 from USD 35.5 billion in 2022, at a -1.4% CAGR.
The reagents, kits, and consumables accounted for the largest market share in the infectious disease diagnostics market, by product & service, during the forecast period
The infectious disease diagnostics market is segmented into reagents, kits, and consumables; instruments; and software & services. The reagents, kits, and consumables segment accounted for the largest market share in the infectious disease diagnostics market in 2021.
Major factors driving the growth of this segment include the increasing number of infectious disease diagnostic tests carried out, the growing need for more reliable, more specific, and faster detection of infectious diseases in the early stages. This is the largest and fastest-growing product segment in the infectious disease diagnostics market. Also, the frequent need for reagents & kits makes it a recurrent cost.
Mosquito-borne diseases segment accounted for the highest CAGR
Based on the disease type, the infectious disease diagnostics market is segmented into COVID-19, HIV, Hospital-acquired infections, hepatitis, Chlamydia trachomatis, Neisseria Gonorrhea, HPV, Tuberculosis, influenza, syphilis, mosquito-borne diseases and other infectious diseases. In 2021, the mosquito-borne diseases segment accounted for the highest CAGR.
Based on end-users, the infectious disease diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, academic research institutes, and other end users. The diagnostic laboratories segment accounted for the largest market share in 2021. This can be attributed to the development of complex and highly specialized tests in infectious disease diagnostics and strengthening healthcare infrastructures for efficient disease diagnosis and treatment.
Market Dynamics
Drivers
- Global Prevalence Of Infectious Diseases
- Rising Focus On R&D And Funding In Infectious Disease Diagnostics
- Growing Awareness For Early Disease Diagnosis In Developing Countries
- Rising Technological Advancements In Infectious Disease Diagnostics
- Shift In Focus From Centralized Laboratories To Decentralized POC Testing
Restraints
- Unfavorable Reimbursement Scenario
Opportunities
- Growth Opportunities In Growing Economies
Challenges
- Changing Regulatory Landscape
- Operational Barriers
- Impact Of Covid-19 On Infectious Disease Diagnostics Market
Companies Mentioned
- Abbott Laboratories (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- bioMerieux SA (France)
- Thermo Fisher Scientific Inc. (US)
- Danaher Corporation (US)
- QuidelCorporation(US)
- Hologic, Inc. (US)
- PerkinElmer Inc. (US)
- Bio-Rad Laboratories, Inc. (US)
- QIAGEN (Netherlands)
- Siemens Healthineers AG (Germany)
- Becton, Dickinson and Company (US)
- DiaSorin S.p.A (Italy)
- Grifols S.A. (Spain)
- Sysmex Corporation (Japan)
- Seegene Inc. (South Korea)
- Ortho Clinical Diagnostics (US)
- Genetic Signatures (Australia)
- Meridian Bioscience (US)
- OraSure Technologies (US)
- Trinity Biotech Plc. (Ireland)
- Chembio Diagnostic Systems (US)
- Co-Diagnostics (US)
- ELITechGroup (France)
- Epitope Diagnostics (US)
- Trivitron Healthcare (India)
- Meril Life Sciences Pvt. Ltd. (India)
- InBios International (US)
- Uniogen Oy (Finland)
- Vela Diagnostics (Singapore)
For more information about this report visit https://www.researchandmarkets.com/r/tevo48
